Advocates ‘appalled’ as CMS again says it will not cover monoclonal antibody treatments for Alzheimer’s
By
Kimberly Bonvissuto
Feb 24, 2023
Advocates of those living with Alzheimer’s disease are expressing disappointment that the Centers for Medicare & Medicaid Services on Wednesday rejected a request to expand its coverage of monoclonal...
More news for Wednesday, Feb. 22
By
Kimberly Bonvissuto
Feb 22, 2023
Congressman tells AG Garland that Esformes case is ‘political’ … FHCA unveils 2023 legislative priorities … Medicare advisers suggest tweak to coverage process for Alzheimer’s drugs … Schumer...
Bipartisan group pushes CMS to expand coverage for Alzheimer’s treatments
By
Kimberly Bonvissuto
Feb 21, 2023
Access to federally approved monoclonal antibody and other disease-modifying therapies for Alzheimer’s disease will be “extremely limited” unless the Centers for Medicare & Medicaid Services reconsiders...
Decision-making on antipsychotic medication use in assisted living needs system-level perspective: study
By
Kimberly Bonvissuto
Jan 25, 2023
Decisions on administering as-needed antipsychotic medications in assisted living/ residential care communities are based on attitudes, underlying morality and perceived expertise, requiring a system-level...
Natural environments may cut hospitalization for patients with neurodegenerative diseases
Dec 30, 2022
The normalized difference vegetation index was negatively associated with hospitalization for Alzheimer’s disease and related dementia as well as Parkinson’s disease.
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.
Lawmakers seek passage of two bills that would help prevent, treat Alzheimer’s
By
Kimberly Bonvissuto
Nov 22, 2022
Two lawmakers are asking for support of two bipartisan bills to ensure the nation has the ability to continue both immediate and long-term planning in its battle against Alzheimer’s disease and related...
More news for Monday, Nov. 7
By
Kimberly Bonvissuto
Nov 07, 2022
HUD opens 5th round of COVID supplemental payments, reduces reimbursements for senior housing … Front Porch expands memory care programs to meet increasing demand … Active adult data now available...
Dementia costs jump 31 percent in a decade, with care needs expected to grow
By
Alicia Lasek
Nov 02, 2022
Despite progress in risk reduction, testing and treatment, the costs of dementia care in the United States continue to rise alongside dementia prevalence, putting the onus on healthcare providers and other...